(6) M H Rasmussen, J Frystyk, T Andersen, L Breum, et al (1994) The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-1 (IGF-1), IGF-binding protein-3, insulin, and growth hormone Metabolism, 1994 Mar, Volume 43 (Issue 3), Pages 315-9
CJC-1295 No DAC functions as a growth hormone releasing hormone analogue that interacts with pituitary receptors responsible for growth hormone signaling
Community glutathione protocols run 200-600 mg by intramuscular or subcutaneous injection 2-3x/week, or 600-2,000 mg by IV infusion weekly to biweekly
Risks and Side Effects of IGF-1 LR3 While IGF-1 LR3 is generally well-tolerated, some individuals may experience mild side effects, such as muscle soreness, fluid retention, hypoglycemia, or insulin resistance